After ASHG, Analysts Say Future is 'Murky' for Expression Arrays, 'Secure' for Genotyping Chips | GenomeWeb

An earlier version of this article attributed a statement to NCGR President Greg May that was actually made by HudsonAlpha investigator Shawn Levy. The story has now been corrected.

By Justin Petrone

The future is uncertain for gene-expression microarrays as applications based on high-throughput sequencers continue to come down in price. At the same time, the market for genotyping chips is less likely to face competition from sequencing, according to two analysts familiar with the industry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.